Circle Cardiovascular Imaging (Circle CVI) has received clearance from the U.S. Food and Drug Administration (FDA) for cvi42 | Plaque, AI software for plaque analysis on coronary CT angiography (CCTA).
cvi42 | Plaque integrates into existing CT workflows and is compatible with all major vendor systems. Ultimately, the software provides clinicians with greater control over their data, improved study processing times, and enhanced workflow efficiency, the company said.
Medicare currently covers AI-enabled coronary plaque analysis from CCTA with Category III CPT code 0625T, but effective January 2026, AI-enabled coronary plaque analysis will be covered by permanent Category I CPT code 75XX6, Circle CVI noted.
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
